Optimizing combination therapy in the management of hypertension: the role of the aliskiren, amlodipine, and hydrochlorothiazide fixed combination.
Optimizing combination therapy in the management of hypertension: the role of the aliskiren, amlodipine, and hydrochlorothiazide fixed combination.
复制标题
DOI：
10.2147/ibpc.s32649
复制
发表时间：
2013
影响因子：
2.2
通讯作者：
Jaimes EA
中科院分区：
文献类型：
--
作者：
Hovater MB;Jaimes EA
高血压是全球死亡和残疾的主要危险因素，患病率正在上升。有效的治疗可以降低不良事件的风险，与血压降低成比例。联合降压治疗可迅速有效地降低血压。与单药药丸相比，单药药丸组合减少了药丸负担，并提高了治疗的依从性、疗效和耐受性。相当一部分高血压人群需要三种药物才能充分控制。阿利吉仑、阿托伐他汀和氢氯噻嗪的单丸组合是基于互补的作用机制。临床试验表明，它是一种安全有效的治疗高血压的方法。对于需要三种药物才能有效治疗的高血压患者，该联合用药是临床上的合理选择。
High blood pressure is the leading risk factor for death and disability worldwide, and the prevalence is increasing. Effective treatment decreases the risk of adverse events in proportion to blood pressure reduction. Combination antihypertensive therapy reduces blood pressure promptly and effectively. Single-pill combinations reduce the pill burden and improve adherence, efficacy, and tolerability of treatment compared with single drug pills. A significant portion of the hypertensive population will require three drugs for adequate control. The single-pill combination of aliskiren, amlodipine, and hydrochlorothiazide is based on complementary mechanisms of action. Clinical trials have shown it to be a safe and effective treatment for hypertension. This combination is a reasonable choice in clinical practice for patients with hypertension that requires three drugs for effective treatment.